Loading viewer...
investor_presentation
Format: PDF investor_presentation
Insmed Incorporated's June 2024 commercial presentation outlines the company's portfolio strategy including ARIKAYCE, their approved inhalation antibiotic product, and pipeline candidates brensocatib and TPIP for nontuberculous mycobacteria and other respiratory infections. The presentation addresses regulatory pathways, commercialization efforts, manufacturing partnerships, and reimbursement strategies for their specialty pharmaceutical products.
investor_presentation
43 Pages
Kinnate Biopharma
Adani Green Energy Limited 2022 Investor Presentation
investor_presentationinvestor_presentation
49 Pages
Adani Green Energy Limited
Gjensidige Forsikring 2016 Investor Presentation
investor_presentationinvestor_presentation
16 Pages
Gjensidige Forsikring ASA